中藥厚朴萃取物外用製劑治療異位性皮膚炎臨床療效評估：前驅性研究

Evaluation of the Clinical Efficacy on Topical Application of the Magnolia officinalis Extract for Atopic Dermatitis: A Pilot Study

王品涵(Pin-Han Wang) ； 魏禎瑩(Chen-Ying Wei) ； 陳俊良(Jiun-Liang Chen) ； 方嘉佑(Jia-You Fang) ； 胡倩婷(Sindy Hu) ； 楊賢鴻(Sien-Hung Yang)

《中醫藥雜誌》 33卷2期 (2022/12) Pp. 82-97

https://doi.org/10.6940/JCM.202212_33(2).06

摘要

目的：探討中藥厚朴萃取物外用製劑治療異位性皮膚炎的臨床療效。方法：本試驗設計為一雙盲、隨機分派、具有安慰劑組的前驅性研究。於某醫院多中心之皮膚科與中醫門診，收治診斷為異位性皮膚炎之大於20歲至65歲患者，以厚朴萃取物軟膏早晚各一次薄塗抹於患處皮膚，治療三個月，觀察其對皮膚症狀、生活品質的改善，並追蹤至治療停止後一個月。結果：共完成收治16人。結果發現，實驗組與對照組SCOring Atopic Dermatitis（SCORAD）總分和Dermatology Life Quality Index（DLQI）分數比較，在試驗第6週、試驗第12週（試驗結束）以及試驗結束後一個月比較，均有顯著改善（p value ＜ 0.05）。結論：中藥厚朴萃取物軟膏外用可改善患者皮膚的症狀及生活品質，且臨床療效可持續至用藥結束後一個月。厚朴萃取物外用治療異位性皮膚炎值得未來更大規模的臨床研究。

關鍵字

異位性皮膚炎 ； 厚朴酚 ； 和厚朴酚 ； 異位性皮膚炎評分量表 ； 皮膚生活品質量表

並列摘要

Purpose: To investigate the clinical efficacy of Magnolia officinalis extract's topical applications in treating atopic dermatitis. Method: This trial was designed as a double-blind, randomized, pilot study with a placebo arm. In a multi-center dermatology and traditional Chinese medicine clinic associated with a hospital, patients aged 20 to 65 years old diagnosed with atopic dermatitis were recruited. M. officinalis ointment was applied to patients' affected skin once every morning and evening for 3 months. Improvements in skin symptoms and quality of life were followed up to one month after the trial. Result: The sample size was 16 patients. The SCOring Atopic Dermatitis (SCORAD) total score and Dermatology Life Quality Index (DLQI) score between the experimental group and the control group were compared at the 6^(th) week of the trial, the 12^(th) week of the trial (the end of the trial) and one month after the trial concluded. The result showed significant improvement (p-value ＜ 0.05). Conclusion: The topical application of M. officinalis extract ointment can improve patients' skin symptoms and quality of life, and the clinical effect can last up to one month after the end of the trial. The topical treatment of atopic dermatitis with M. officinalis extract should be further studied in larger-scale clinical research in the future.

並列關鍵字

atopic dermatitis ； magnolol ； honokiol ； SCOring Atopic Dermatitis (SCORAD) ； dermatology Life Quality Index (DLQI)

參考文獻

Hwang CY, Chen YJ, Lin MW, et al. Prevalence of atopic dermatitis, allergic rhinitis and asthma in Taiwan: a national study 2000 to 2007. Acta. Derm. Venereol. 2010; 90(6): 589-594.

Ali F, Vyas J, Finlay AY. Counting the Burden: Atopic Dermatitis and Health-related Quality of Life. Acta. Derm. Venereol. 2020; 100(12): adv00161.

Hsieh BJ, Shen D, Hsu CJ, et al. The impact of atopic dermatitis on health-related quality of life in Taiwan. J. Formos. Med. Assoc. 2022; 121(1 Pt 2): 269-277.

Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J. Clin. Invest. 2004; 113(5): 651-657.

Fishbein AB, Silverberg JI, Wilson EJ, et al. Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection. J. Allergy Clin. Immunol. Pract. 2020; 8(1): 91-101.